**Name of Journal:** *World Journal of Gastrointestinal Oncology*

**Manuscript NO:** 85901

**Manuscript Type:** ORIGINAL ARTICLE

***Retrospective Study***

**Baseline neutrophil-lymphocyte ratio and platelet-lymphocyte ratio appear predictive of immune treatment related toxicity in hepatocellular carcinoma**

Dharmapuri S *et al.* Inflammatory biomarkers and immune treatment toxicity

Sirish Dharmapuri, Umut Özbek, Hiren Jethra, Tomi Jun, Thomas U Marron, Anwaar Saeed, Yi-Hsiang Huang, Mahvish Muzaffar, Matthias Pinter, Lorenz Balcar, Claudia Fulgenzi, Suneetha Amara, Arndt Weinmann, Nicola Personeni, Bernhard Scheiner, Tiziana Pressiani, Musharraf Navaid, Bertram Bengsch, Sonal Paul, Uqba Khan, Dominik Bettinger, Naoshi Nishida, Yehia Ibrahim Mohamed, Arndt Vogel, Anuhya Gampa, James Korolewicz, Antonella Cammarota, Ahmed Kaseb, Peter R. Galle, Anjana Pillai, Ying-Hong Wang, Alessio Cortellini, Masatoshi Kudo, Antonio D’Alessio, Lorenza Rimassa, David James Pinato, Celina Ang

**Sirish Dharmapuri, Thomas U Marron, Celina Ang,** Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, United States

**Umut Özbek,** Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, NY 10029, United States

**Hiren Jethra,** Department of Data Analytics Harrisburg, Harrisburg University of Science and Technology, Harrisburd, PA 17101, United States

**Tomi Jun,** SEMA4, Stamford, CT 06902, United States

**Anwaar Saeed,** Division of Medical Oncology Kansas, University of Kansas Cancer Center, Kansas, MO 66160, United States

**Yi-Hsiang Huang,** Division of Gastroenterology and Hepatology, Taipei Veterans General Hospital, Taipei 11217, Taiwan

**Mahvish Muzaffar, Suneetha Amara, Musharraf Navaid,** Department of Internal Medicine, Brody School of Medicine, East Carolina University, Greenville, NC 27858, United States

**Matthias Pinter, Lorenz Balcar, Bernhard Scheiner,** Department of Internal Medicine III, Division of Gastroenterology and Hepatology, Medical University of Vienna, Vienna 1090, Austria

**Claudia Fulgenzi, Alessio Cortellini, Antonio D’Alessio, David James Pinato, James Korolewicz,** Department of Surgery and Cancer, Imperial College London, Hammersmith Hospital London, London W12 0HS, United Kingdom

**Arndt Weinmann,** Department of Hepatology, Johannes Gutenberg-University Medical Centre, Niedersachsen 30625, Germany

**Nicola Personeni,** Medical Oncology Unit, ASST Garda, Via Lungomella Valsecchi, Brescia, Manerbio 25025, Italy

**Nicola Personeni, Tiziana Pressiani, Antonella Cammarota, Lorenza Rimassa,** Medical Oncology and Hematology Unit, Humanitas Cancer Center, IRCCS Humanitas Research Hospital, Milan, Rozzano 20089, Italy

**Bertram Bengsch, Dominik Bettinger,** Department of Medicine II, Univ Med Ctr Freiburg, Hugstetter Str 55, University Hospital Freiburg, Freiburg D-79106, Germany

**Sonal Paul,** Department of Oncology Baltimore, LifeBridge Health, Baltimore, MD 21215, United States

**Uqba Khan,** Division of Hematology and Oncology, Weill Cornell Medical College, NY 10065, United States

**Naoshi Nishida, Masatoshi Kudo,** Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka 577-8502, Japan

**Yehia Ibrahim Mohamed, Ahmed Kaseb,** Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States

**Arndt Vogel,** Department of Gastroenterology Hepatology and Endocrinology, HannoverArndt Vogel, Medical School Hannover, Carl-Neubergstr., Hannover 30659, Germany

**Anuhya Gampa,** Department of Hepatology, Rush University Medical Group 1725 W Harrison St Ste 158, Chicago, IL 60612, United States

**Antonella Cammarota, Lorenza Rimassa,** Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, Milan, Pieve Emanuele 20072, Italy

**Peter R. Galle,** Department of Internal Medicine I and Cirrhosis Center Mainz, University Medical Center Mainz, Johannes Gutenberg Univ Mainz, Med Klin and Poliklin, Mainz D-55131, Germany

**Anjana Pillai,** Department of Gastroenterology, Hepatology, and Nutrition, University of Chicago Medical Center, Chicago, IL 60637, United States

**Ying-Hong Wang,** Department of Gastroenterology, Hepatology and Nutrition, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States

**Author contributions:** Dharmapuri S contributed to study concept and design, acquisition of data, analysis, and interpretation of data and drafting of the manuscript; Özbek U and Jethra H performed statistical analysis; Jun T, Marron TU, Saeed A, Huang YH, Muzaffar M, Pinter M, Balcar L, Fulgenzi C, Amara S, Weinmann A, Personeni N, Scheiner B, Pressiani T, Navaid M, Bengsch B, Paul S, Khan U, Bettinger D, Nishida N, Mohamed YI, Vogel A, Gampa A, Korolewicz J, Cammarota C, Kaseb A, Galle PR, Pillai A, Wang YH, Cortellini A, Kudo M, D’Alessio A and Rimassa L performed acquisition of data; Pinato DJ and Ang C contributed to study concept and design, analysis and interpretation of data, drafting of the manuscript, and study supervision; Both contributed equally and should be considered joint senior authors. All authors performed critical revision of the manuscript for important intellectual content.

**Corresponding author: Sirish Dharmapuri, MD, Assistant Professor,** Tisch Cancer Institute, Icahn school of Medicine at Mount Sinai, No. 425 West 59th Street, New York, NY 10029, United States. sirish.dharmapuri@gmail.com

**Received:** May 21, 2023

**Revised:** September 14, 2023

**Accepted:** October 23, 2023

**Published online:**

**Abstract**

BACKGROUND

A well-recognized class effect of immune checkpoint inhibitors (ICI) is immune-related adverse events (IrAEs) ranging from low grade toxicities to life-threatening end organ damage requiring permanent discontinuation of ICI. Deaths are reported in < 5% of patients treated with ICI. There are, however, no reliable markers to predict the onset and severity of IrAEs. We tested the association between neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR) at baseline with development of clinically significant IrAEs (grade ≥ 2) in hepatocellular carcinoma (HCC) patients treated with ICI.

AIM

To test the association between NLR and PLR at baseline with development of clinically significant IrAEs (grade ≥ 2) in HCC patients treated with ICI.

METHODS

Data was extracted from an international database from a consortium of 11 tertiary-care referral centers. NLR = absolute neutrophil count/absolute lymphocyte count (ALC) and PLR = platelet count/ALC. Cutoff of 5 was used for NLR and 300 for PLR based on literature. We also tested the association between antibiotic and steroid exposure to IrAEs.

RESULTS

Data was collected from 361 patients treated between 2016-2020 across the United States (67%), Asia (14%) and Europe (19%). Most patients received Nivolumab(*n* = 255, 71%). One hundred sixty-seven (46%) patients developed at least one IrAE, highest grade 1 in 80 (48%), grade ≥ 2 in 87 (52%) patients. In a univariable regression model PLR > 300 was significantly associated with a lower incidence of grade ≥ 2 IrAEs (OR = 0.40; *P* = 0.044). Similarly, a trend was observed between NLR > 5 and lower incidence of grade ≥ 2 IrAEs (OR = 0.58; *P* = 0.097). Multivariate analyses confirmed PLR > 300 as an independent predictive marker of grade ≥ 2 IrAEs (OR = 0.26; *P* = 0.011), in addition to treatment with programmed cell death ligand 1 (PD-1)/cytotoxic T lymphocyte-associated protein-4 (OR = 2.57; *P* = 0.037) and PD-1/tyrosine kinase inhibitor (OR = 3.39; *P* = 0.01) combinations. Antibiotic use was not associated with IrAE incidence (OR = 1.02; *P* = 0.954). Patients treated with steroids had a > 2-fold higher incidence of grade ≥ 2 IrAEs (OR = 2.74; *P* < 0.001), although 74% were prescribed steroids for the treatment of IrAEs.

CONCLUSION

Given that high baseline NLR and PLR are associated with a decreased incidence of IrAEs, lower baseline NLR and PLR may be predictive biomarkers for the appearance of IrAEs in HCC treated with ICI. This finding is in keeping with several studies in solid tumors that have shown that baseline NLR and PLR appear predictive of IrAEs.

**Key Words:** Neutrophil-lymphocyte ratio; Platelet-lymphocyte ratio; Inflammatory biomarkers; Immunotherapy; Immune toxicity

Dharmapuri S, Özbek U, Jethra H, Jun T, Marron TU, Saeed A, Huang YH, Muzaffar M, Pinter M, Balcar L, Fulgenzi C, Amara S, Weinmann A, Personeni N, Scheiner B, Pressiani T, Navaid M, Bengsch B, Paul S, Khan U, Bettinger D, Nishida N, Mohamed YI, Vogel A, Gampa A, Korolewicz J, Cammarota A, Kaseb A, Galle PR, Pillai A, Wang YH, Cortellini A, Kudo M, D’Alessio A, Rimassa L, Pinato DJ, Ang C. Baseline neutrophil-lymphocyte ratio and platelet-lymphocyte ratio appear predictive of immune treatment related toxicity in hepatocellular carcinoma. *World J Gastrointest Oncol* 2023; In press

**Core Tip:** In this study of hepatocellular carcinoma (HCC) patients treated with immune checkpoint inhibitors (ICI), the association between two biomarkers, neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR), and immune-related adverse events (IrAEs) was examined. Data from 361 patients showed that a higher PLR (> 300) was significantly associated with a lower incidence of grade ≥ 2 IrAEs. A trend was observed between a higher NLR (> 5) and lower incidence of grade ≥ 2 IrAEs. Multivariate analyses confirmed PLR as an independent predictive marker for grade ≥ 2 IrAEs. These findings suggest that NLR and PLR could be potential predictive markers for IrAEs in HCC patients receiving ICI treatment.

**INTRODUCTION**

Hepatocellular carcinoma (HCC) arises in a precancerous milieu of chronic inflammation heralded by oncoviral infection, alcohol consumption or steatohepatitis in up to 90% of patients[1-3]. Systemic inflammatory response driven by pro-inflammatory cytokines such as vascular endothelial growth factor (VEGF), matrix metalloproteinases and interleukin-18 plays a pivotal role in oncogenesis as well as tumor progression and metastasis[3-5].

Immune checkpoint inhibitors (ICI) and their combinations can induce robust and durable anti-tumor responses in a subset of patients with advanced Hepatocellular Carcinoma (aHCC). The IMbrave-150 and HIMALAYA trials both showed significantly improved progression free and overall survival with ICI combinations compared to sorafenib, making atezolizumab/bevacizumab and durvalumab/tremelimumab standard front-line options[6]. ICI monotherapies such as nivolumab and pembrolizumab remain an integral part of the treatment paradigm owing to their safety, tolerability and improved quality of life over tyrosine kinase inhibitors[6-9]. With the advent of ICI as the mainstay of treatment of aHCC, considerable interest has been generated towards studying the relationship between inflammation and its impact on outcomes of patients treated with ICIs.

A well-recognized class effect of these drugs is immune treatment-related adverse events (IrAEs) ranging from low grade toxicities managed supportively with or without steroids or other immunosuppressive agents to potentially life-threatening end organ damage requiring hospitalization and permanent discontinuation of ICI. Treatment related deaths are reported in less than 5% of patients treated with ICIs [Yervoy® (ipilimumab) prescribing information. Bristol-Myers Squibb Company. Princeton, NJ, United States (2013)][10-12]. At present, there are no reliable markers to predict the onset and severity of IrAEs. This study was undertaken with the objective of examining the relationship between inflammatory ratios such as neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR) with the incidence of IrAEs in aHCC patients treated with ICIs. In addition, given recent data demonstrating that steroids can modulate NLR[13] and that antibiotics may increase the risk of IrAEs[14,15], we also aimed to explore the interaction between these drugs, NLR, PLR and IrAEs.

**MATERIALS AND METHODS**

***Patients***

Data was extracted from a large international database from a consortium of 11 tertiary-care referral centers located in the United States, Europe and Asia. To be eligible patients had to have: (1) A diagnosis of HCC made by histopathology or imaging criteria according to international guidelines; (2) be candidate for ICI monotherapy or combinations for HCC; (3) not amenable to curative or loco-regional therapy following local multidisciplinary tumor board review, and (4) have measurable disease according to RECIST 1.1 criteria. Between June 2016 and September 2020, 427 patients were included in the database. In our final analysis we excluded 66 patients due to incomplete IrAE data (final *n* = 361). Of the 361 patients included in the final analysis, 242 (67%) were treated in the United States, 51 (14%) in Asia and 68 (19%) in Europe. Institutional review board approval was obtained at Mount Sinai Hospital and in each participating institution. All study-related procedures and data collection were conducted in accordance with the Declaration of Helsinki and in accordance with good clinical practice.

***Methods***

NLR was calculated as the ratio of absolute neutrophil count to absolute lymphocyte count (ALC), and PLR was calculated as the ratio of platelet count to ALC from blood draws at baseline. A cutoff of 5 was used for NLR groups and 300 for PLR based on literature[16-20]. Information regarding IrAEs was extracted by manual review of clinical documentation at each cycle and records of hospitalizations. Each IrAE was defined and documented per the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) v5.0 per the treating physician and validated by a member of the study group. Grade ≥ 2 IrAEs were considered clinically significant since these patients typically require close monitoring and/or initiation of corticosteroid therapy and/or permanent discontinuation of ICI, while grade 1 toxicities only require supportive measures.

Patients were considered exposed to corticosteroid if > 10 mg of prednisone (or equivalent) was administered for > 24 h within 30 d prior to or concomitantly until permanent cessation of immunotherapy. Similarly, patients were considered to have been exposed to antibiotic therapy if they were received within 30 d from starting ICI therapy and up to 30 d after cycle 1 of immunotherapy were based on literature which suggests early antibiotic exposure as a detrimental factor influencing ICI efficacy[21,22].

***Statistical analysis***

Descriptive statistics were calculated to summarize baseline status, including demographics, disease characteristics, and treatment characteristics. Univariable logistic models were conducted to identify associations between adverse events, inflammatory scores and other baseline characteristics. Continuous variables were presented as medians and minimum-maximum values, and categorical variables as frequency and proportions. Clinically relevant variables such as baseline alpha-fetoprotein (AFP), barcelona clinic liver cancer stage, presence of cirrhosis, child-turcotte pugh class, eastern cooperative oncology group performance status, etiology of chronic liver disease, and use of corticosteroids and antibiotics for IrAE management were considered as predictors of toxicity and were analyzed by univariable and multivariable logistic regression models. *P* values of less than 0.05 were considered to indicate statistical significance. All analyses were performed using R statistical package version 4.0.3 (R Core Team 2020)[23].

**RESULTS**

***Patient and disease characteristics***

A total of 361 patients had documented IrAE data and were included in the final analysis, of whom 242 (67%) were treated in the United States, 51 (14%) in Asia and 68 (19%) in Europe (Figure 1). Table 1 shows the breakdown of key clinicopathologic characteristics in patients who had none or grade < 2 and grade ≥ 2 IrAEs. A majority had underlying cirrhosis (*n* = 263, 73%). Two hundred and seventy-six (76%) patients had child-pugh class A and 74 (20%) had class B liver function. The most common etiologies were hepatitis C virus infection in 153 (42%) patients, followed by hepatitis B virus infection in 77 (21%). Most patients received programmed cell death ligand 1 (PD-1) monotherapy (*n* = 305, 84%; nivolumab = 255; pembrolizumab = 20), followed by combination PD-1/cytotoxic T lymphocyte-associated protein-4 (CTLA-4) (*n* = 28, 8%), PD-1/tyrosine kinase inhibitor (TKI) (*n* = 24, 7%) and others in 4 (1%).

***IrAEs***

One hundred and sixty-seven (46%) patients were documented as having developed at least one IrAE, highest grade 1 in 80 (48%), grade 2 or higher in 87 (52 %) patients. There was one treatment related death reported. The most common IrAE was hepatitis (41%) followed by constitutional symptoms including fatigue, anorexia, chills (40%). Table 2 details the IrAE incidence by groups and severity. No significant differences in age, sex, risk factors including Ethanol, hepatitis B and C, presence of cirrhosis, portal vein thrombosis and median AFP were noted between patients who developed IrAEs of grade ≥ 2 and those who did not.

Treatment with combinations PD-1/CTLA-4 and PD-1/TKI were associated with a 3 (OR = 3; *P* = 0.007) and 4-fold (OR = 4; *P* = 0.001) higher incidence of grade ≥ 2 IrAEs over PD-1 only. In a multivariable regression analysis, treatment with both PD-1/CTLA-4 (OR = 2.57; *P* = 0.037) and PD-1/TKI (OR = 3.39; *P* = 0.01) were independently associated with incidence of grade ≥ 2 IrAEs.

***Relationship between NLR, PLR and IrAEs***

NLR was ≤ 5 in 184 (51%) patients and > 5 in 70 (20%) patients. The proportion of patients with an NLR < 5 or > 5 did not differ significantly between the IrAE groups. PLR was ≤ 300 in 217 (60%) and > 300 in 37 (11%) patients (Table 1). In a univariable regression model, baseline PLR > 300 was significantly associated with a lower incidence of grade ≥ 2 IrAEs (OR = 0.40; *P* = 0.044). Similarly, NLR > 5 was associated with a trend toward lower incidence of grade ≥ 2 IrAEs (OR = 0.58; *P* = 0.097). The multivariable regression analysis showed an independent association between PLR > 300 (OR = 0.26; *P* = 0.011) with a lower incidence of grade 2 or higher IrAEs (Table 3).

***Impact of concomitant medications on NLR, PLR and IrAEs***

A total of 94 patients received corticosteroids, including 47 patients who developed an IrAE. Steroid use was associated with a greater than 2-fold higher incidence of grade ≥ 2 IrAEs (OR = 2.74; *P* < 0.001) and maintained a significant association in a multivariable regression analysis (OR = 4.43; *P* < 0.001). Notably, the indication for steroids in 35 (74%) of the 47 patients who developed an IrAE, was for the treatment of IrAEs.

Fifty-six patients received antibiotics for treatment of an infection or as pre-transarterial chemoembolisation prophylaxis. Twenty-nine of these patients had documented IrAEs. Antibiotics use was not associated with IrAE incidence (OR = 1.02; *P* = 0.954) (Table 3).

NLR and PLR did not differ significantly between patients who did and did not receive steroids [(NLR; HR = 1.03; *P* = 0.69) (PLR; HR = 1.04; *P* = 0.53)] or antibiotics [(NLR; HR = 1.13; *P* = 0.35) (PLR; HR = 1.21; *P* = 0.10)].

**DISCUSSION**

ICIs induce a diverse array of toxicities, presenting as single organ inflammatory disease such as hepatitis to multi system toxicity[24]. Most IrAEs present within the first few months of therapy, though they can manifest throughout the course of treatment[25,26]. They most frequently affect barrier tissues such as the skin (-20%)[26], gastrointestinal tract (-50%)[27] and the respiratory epithelium (-35%), followed by endocrine organs (6%-12%)[28] and less frequently cause joint inflammation (-10%), neurological, cardiovascular or hematologic toxicity (1%-5%). Treatment related deaths are also reported in < 5% of patients treated with ICI[24,25].

Currently, there are no prospectively validated biomarkers to predict the onset or the severity of IrAEs though several have been studied such as preexisting autoimmune disease, body-mass index, and gut microbiome among others[29,30]. Onset of IrAEs however, closely correlates with clinical benefit from ICI therapy based on several reports across disease types[31-38], including from our consortium[39]. Conversely, inflammatory ratios such as NLR and PLR have consistently demonstrated an inverse relationship with response and survival outcomes from ICI therapy[40,41]. Considering the correlation between these inflammatory ratios and IrAEs, as well as the broad accessibility, ease of execution, and rapidity of these tests, it is pertinent to study the relationship between these inflammatory ratios and IrAEs.

Our study demonstrates, for the first time, a potential inverse association between baseline PLR and NLR with incidence of clinically significant (*i.e.*, grade ≥ 2) IrAEs in aHCC treated with ICI, particularly for PLR which was an independent predictive marker of grade ≥ 2 IrAEs. Such an association has also been described in other diseases, particularly in non-small cell lung cancer[42-44]. While the individual relationships between NLR, PLR, IrAE incidence and ICI response directionally align with the existing literature, the mechanisms linking the systemic inflammatory response and the development of IrAEs require further study.

An elevated NLR in a chronic inflammatory state such as cancer, has been shown to be associated with an increased concentration of polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs) in the peripheral blood[45] as well as tumor-infiltrating neutrophils[43]. The role of PMN-MDSCs in immune tolerance by means of upregulated expression of arginase-1, increased production of reactive oxygen species, Nitrous Oxide, prostaglandin E2 among others is well described in literature[46]. It may therefore be reasonable to hypothesize that the suppression of the anti-tumor T lymphocyte responses in the tumor microenvironment heralded by PMN-MDSCs likely contributes to the poor clinical outcomes and a lower incidence of IrAEs. Additionally, Lymphocytes are an integral components in the immune response against tumors, and an elevated presence of tumor-infiltrating lymphocytes within the neoplastic tissue holds prognostic value, correlating with improved survival outcomes[47]. Patients with higher NLR and PLR have a state of relative lymphopenia, signifying an impaired immune response. This likely accounts for both a reduced incidence of IrAEs as well as poorer prognostic outcomes on ICI.

The mechanistic rationale for the predictive nature of PLR is less well understood, though may be partly explained by the hypercortisolemic state of chronic inflammatory disease[48]. Hypercortisolemia results in elevated platelet counts, heightened platelet activation, and concurrently lowers lymphocyte counts[49-51]. Thrombocytosis has been demonstrated to exert pro-tumor effects, facilitating tumor progression and metastasis through the production of VEGF and platelet-derived growth factor production. These factors subsequently recruit neutrophils and monocytes, a phenomenon that ultimately culminates in adverse prognostic outcomes[40,52]. Beyond their role in hemostasis, platelets modulate the immune response *via* both pro and anti-inflammatory mechanisms. Platelets have been shown to express functional CD154, a molecule critical for primary and memory T cell responses[53]. In addition to acting as antigen presenting cells[54], platelets also augment CD8 T cell responses *via* CD154 mediated secondary signaling[55]. Their anti-inflammatory effect is exerted *via* platelet-derived cytokine TGF β which inhibits FoxP3(-) T-cells, among other mechanisms[56]. The vast role of platelets in immune modulation remains underrepresented in literature.

Consistent with published literature[24,57], our study shows a 2 to 3-fold higher incidence of grade ≥ 2 IrAEs in patients receiving ICI combinations over monotherapy. In the HIMALAYA trial, the incidence of any grade toxicity was 76% in the combination arm, as opposed to 52% in the durvalumab only arm[58]. Similarly, combination Atezolizumab–bevacizumab led to any grade toxicity rate of 98% in the IMbrave-150 study[6]. Understanding how to balance the toxicity of ICI and its combinations, while maximizing its anti-tumor activity remains a critical unmet need and may hinge on identifying early predictors of impending toxicity.

Our study also demonstrates that the use of steroids was strongly associated with a 2-fold increase in the incidence of grade > 2 IrAEs. However, of the 47 patients with IrAEs who received steroids, 74% were prescribed them for treatment of IrAEs. Thus, the association is likely explained by steroids being used to treat IrAEs and does not indicate a causal relationship. Due to the small number of patients treated with steroids, a distinct analysis of the impact of steroid exposure before ICI therapy *vs* its use in the management of IrAEs is not feasible.

Antibiotic exposure has been shown to impair efficacy of ICI and increase the risk of IrAEs by inducing loss of gut microbial diversity and dysbiosis[59,60]. Our study showed no association between antibiotic exposes and IrAE risk. Another study published from this consortium also showed an improved progression free survival in patients with early antibiotic exposure while on ICI therapy[21], contrasting with studies in other solid tumors. HCC is associated with an immunosuppressive microbiome in the setting of underlying cirrhosis, which may explain the differential effect of antibiotics compared to other solid tumors[21]. We also noted no significant differences in NLR and PLR between patients who did and did not receive steroids and antibiotics.

We understand the limitations of our study include its retrospective design, a relatively small sample size and lack of correlative studies. Our non-prospective design precludes definitive conclusions regarding the predictive value of NLR and PLR but can be considered hypothesis-generating and warrants further validation in larger, prospective cohorts. Despite the fact that most patients in our study were treated with ICI monotherapy, which contrasts with the current standard of care of atezolizumab-bevacizumab, the findings remain significant as ICIs are a crucial component of the treatment paradigm for HCC. Data were collected and entered manually; some missing IrAE data were noted in our analyses. History regarding other chronic inflammatory conditions that could affect NLR and PLR were not collected during chart review and therefore cannot be evaluated. The influence of other confounding factors such as thrombocytopenia from chronic liver disease on NLR and PLR remains a subject of investigation to be explored in a larger prospective cohort. The documentation of IrAEs was based on the NCI-CTCAE v5.0 per the treating physician and validated by a member of the study group, however inconsistencies may exist due to the subjective nature of some groups of IrAEs.

In conclusion, our study demonstrates an interesting association between baseline inflammatory ratios and onset of IrAEs in a real-world cohort of HCC patients, although this conclusion warrants prospective validation. Given that high baseline NLR and PLR are associated with a lower incidence of clinically significant IrAEs, lower baseline NLR and PLR may be predictive biomarkers for the appearance of IrAEs in HCC treated with ICI. These findings have potentially important implications, as identifying and monitoring patients at high risk of developing IrAEs may help decrease mortality and morbidity associated with IrAE. Our findings also provide real world evidence for increased toxicity of ICI combinations over monotherapy in HCC.

**CONCLUSION**

In conclusion, our study demonstrates an interesting association between baseline inflammatory ratios and onset of IrAEs in a real-world cohort of HCC patients, although this conclusion warrants prospective validation. Given that high baseline NLR and PLR are associated with a lower incidence of clinically significant IrAEs, lower baseline NLR and PLR may be predictive biomarkers for the appearance of IrAEs in HCC treated with ICI. These findings have potentially important implications, as identifying and monitoring patients at high risk of developing IrAEs may help decrease mortality and morbidity associated with IrAE. Our findings also provide real world evidence for increased toxicity of ICI combinations over monotherapy in HCC.

**ARTICLE HIGHLIGHTS**

***Research background***

Immune checkpoint inhibitors (ICI) are known to cause immune-related adverse events (IrAEs) ranging from mild to severe, sometimes leading to treatment discontinuation, with less than 5% of patients experiencing fatal outcomes. Nevertheless, there are currently no dependable markers to forecast the occurrence and seriousness of IrAEs.

***Research motivation***

Nevertheless, there are currently no dependable markers to forecast the occurrence and seriousness of IrAEs.

***Research objectives***

In this study, we examined whether baseline neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR) are linked to the development of clinically significant IrAEs (grade ≥ 2) in patients with hepatocellular carcinoma (HCC) undergoing ICI treatment.

***Research methods***

Data was gathered from a global database comprising data from 11 specialized medical centers. NLR was calculated as the absolute neutrophil count divided by the absolute lymphocyte count (ALC), while PLR was calculated as the platelet count divided by ALC, with predefined cutoff values of 5 for NLR and 300 for PLR as per existing literature. Additionally, we explored the connection between the use of antibiotics and steroids with the occurrence of IrAEs.

***Research results***

Data was collected from 361 patients treated between 2016 and 2020 across the United States (67%), Asia (14%), and Europe (19%), with the majority receiving Nivolumab (71%). Of these patients, 46% experienced at least one IrAE, with 48% being grade 1 and 52% grade ≥ 2. In a univariable regression analysis, a PLR > 300 was significantly linked to a lower incidence of grade ≥ 2 IrAEs (OR = 0.40; *P* = 0.044), while there was a trend towards lower incidence with NLR > 5 (OR = 0.58; *P* = 0.097). Multivariate analysis confirmed PLR > 300 as an independent predictor of grade ≥ 2 IrAEs (OR = 0.26; *P* = 0.011), along with treatment involving programmed cell death ligand 1 (PD-1)/cytotoxic T lymphocyte-associated protein-4 (OR = 2.57; *P* = 0.037) and PD-1/tyrosine kinase inhibitor combinations (OR = 3.39; *P* = 0.01). The use of antibiotics did not show a significant association with IrAE incidence (OR = 1.02; *P* = 0.954), while patients treated with steroids had more than a twofold increased risk of grade ≥ 2 IrAEs (OR = 2.74; *P* < 0.001), although a majority of them received steroids for IrAE treatment.

***Research conclusions***

Considering that elevated baseline NLR and PLR are correlated with a reduced occurrence of IrAEs, lower baseline NLR and PLR levels could potentially serve as predictive biomarkers for the development of IrAEs in HCC patients undergoing ICI treatment.

***Research perspectives***

Considering that elevated baseline NLR and PLR are correlated with a reduced occurrence of IrAEs, lower baseline NLR and PLR levels could potentially serve as predictive biomarkers for the development of IrAEs in HCC patients undergoing ICI treatment.

**REFERENCES**

1 **Chidambaranathan-Reghupaty S**, Fisher PB, Sarkar D. Hepatocellular carcinoma (HCC): Epidemiology, etiology and molecular classification. *Adv Cancer Res* 2021; **149**: 1-61 [PMID: 33579421 DOI: 10.1016/bs.acr.2020.10.001]

2 **Schütte K**, Bornschein J, Malfertheiner P. Hepatocellular carcinoma--epidemiological trends and risk factors. *Dig Dis* 2009; **27**: 80-92 [PMID: 19546545 DOI: 10.1159/000218339]

3 **Dhanasekaran R**, Bandoh S, Roberts LR. Molecular pathogenesis of hepatocellular carcinoma and impact of therapeutic advances. *F1000Res* 2016; **5** [PMID: 27239288 DOI: 10.12688/f1000research.6946.1]

4 **Tangkijvanich P**, Thong-Ngam D, Mahachai V, Theamboonlers A, Poovorawan Y. Role of serum interleukin-18 as a prognostic factor in patients with hepatocellular carcinoma. *World J Gastroenterol* 2007; **13**: 4345-4349 [PMID: 17708609 DOI: 10.3748/wjg.v13.i32.4345]

5 **Diakos CI**, Charles KA, McMillan DC, Clarke SJ. Cancer-related inflammation and treatment effectiveness. *Lancet Oncol* 2014; **15**: e493-e503 [PMID: 25281468 DOI: 10.1016/S1470-2045(14)70263-3]

6 **Finn RS**, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, Kudo M, Breder V, Merle P, Kaseb AO, Li D, Verret W, Xu DZ, Hernandez S, Liu J, Huang C, Mulla S, Wang Y, Lim HY, Zhu AX, Cheng AL; IMbrave150 Investigators. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. *N Engl J Med* 2020; **382**: 1894-1905 [PMID: 32402160 DOI: 10.1056/NEJMoa1915745]

7 **Finn RS,** Ryoo B-Y, Merle P, Kudo M, Bouattour M, Lim H-YJ, Breder V, Edeline J, Chao Y, Ogasawara S, Yau T, Garrido M, Chan SL, Knox J, Daniele B, Ebbinghaus SW, Chen E, Siegel AB, Zhu AX, Cheng AL. Results of KEYNOTE-240: phase 3 study of pembrolizumab (Pembro) vs best supportive care (BSC) for second line therapy in advanced hepatocellular carcinoma (HCC). *Journal of Clinical Oncology* 2019; **37** Suppl 15: 4004-4004 [DOI: 10.1200/JCO.2019.37.15\_suppl.4004]

8 **Yau T**, Kang YK, Kim TY, El-Khoueiry AB, Santoro A, Sangro B, Melero I, Kudo M, Hou MM, Matilla A, Tovoli F, Knox JJ, Ruth He A, El-Rayes BF, Acosta-Rivera M, Lim HY, Neely J, Shen Y, Wisniewski T, Anderson J, Hsu C. Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib: The CheckMate 040 Randomized Clinical Trial. *JAMA Oncol* 2020; **6**: e204564 [PMID: 33001135 DOI: 10.1001/jamaoncol.2020.4564]

9 Yau T, Park JW, Finn RS, Cheng AL, Mathurin P, Edeline J, Kudo M, Han KH, Harding JJ, Merle P, Rosmorduc O, Wyrwicz L, Schott E, Choo SP, Kelley RK, Begic D, Chen G, Neely J, Anderson J, Sangro B. CheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) *vs* sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC). *Annals of Oncology* 2019; **30**: v874-v5 [DOI:10.1093/annonc/mdz394.029]

10 **Opdivo (nivolumab) prescribing information.** Bristol-Myers Squibb Company. **Princeton,** NJ, United States; 2015

11 **Yervoy® (ipilimumab) prescribing information.** Bristol-Myers Squibb Company**. Princeton,** NJ, United States; 2013

12 **Inno A**, Metro G, Bironzo P, Grimaldi AM, Grego E, Di Nunno V, Picasso V, Massari F, Gori S. Pathogenesis, clinical manifestations and management of immune checkpoint inhibitors toxicity. *Tumori* 2017; **103**: 405-421 [PMID: 28497847 DOI: 10.5301/tj.5000625]

13 **Marté JL**, Toney NJ, Cordes L, Schlom J, Donahue RN, Gulley JL. Early changes in immune cell subsets with corticosteroids in patients with solid tumors: implications for COVID-19 management. *J Immunother Cancer* 2020; **8** [PMID: 33219091 DOI: 10.1136/jitc-2020-001019]

14 **Jing Y**, Chen X, Li K, Liu Y, Zhang Z, Chen Y, Liu Y, Wang Y, Lin SH, Diao L, Wang J, Lou Y, Johnson DB, Chen X, Liu H, Han L. Association of antibiotic treatment with immune-related adverse events in patients with cancer receiving immunotherapy. *J Immunother Cancer* 2022; **10** [PMID: 35058327 DOI: 10.1136/jitc-2021-003779]

15 **Mohiuddin JJ**, Chu B, Facciabene A, Poirier K, Wang X, Doucette A, Zheng C, Xu W, Anstadt EJ, Amaravadi RK, Karakousis GC, Mitchell TC, Huang AC, Shabason JE, Lin A, Swisher-McClure S, Maity A, Schuchter LM, Lukens JN. Association of Antibiotic Exposure With Survival and Toxicity in Patients With Melanoma Receiving Immunotherapy. *J Natl Cancer Inst* 2021; **113**: 162-170 [PMID: 32294209 DOI: 10.1093/jnci/djaa057]

16 **Fiala O**, Hosek P, Korunkova H, Hora M, Kolar J, Windrichova J, Sorejs O, Topolcan O, Travnicek I, Sedlackova H, Finek J. Enzalutamide or Abiraterone Acetate With Prednisone in the Treatment of Metastatic Castration-resistant Prostate Cancer in Real-life Clinical Practice: A Long-term Single Institution Experience. *Anticancer Res* 2023; **43**: 463-471 [PMID: 36585174 DOI: 10.21873/anticanres.16183]

17 **Song A**, Eo W, Lee S. Comparison of selected inflammation-based prognostic markers in relapsed or refractory metastatic colorectal cancer patients. *World J Gastroenterol* 2015; **21**: 12410-12420 [PMID: 26604648 DOI: 10.3748/wjg.v21.i43.12410]

18 **Pinato DJ**, Shiner RJ, Seckl MJ, Stebbing J, Sharma R, Mauri FA. Prognostic performance of inflammation-based prognostic indices in primary operable non-small cell lung cancer. *Br J Cancer* 2014; **110**: 1930-1935 [PMID: 24667648 DOI: 10.1038/bjc.2014.145]

19 **Giordano G,** Vaccaro V, Lucchini E, Bertocchi P, Bergamo F, Musettini G, Santoni M, Lo Re G, Giommoni E, Russano M, Campidoglio S, Santini D, Vasile E, Cascinu S, Zagonel V, Zaniboni A, Melisi D, Milella M, Febbraro A. Analysis of prognostic factors in advanced pancreatic cancer (APDAC) patients (pts) undergoing to first-line nab-paclitaxel (Nab-P) and gemcitabine (G) treatment. *Journal of Clinical Oncology* 2015; **33** Suppl 3: 412-412 [DOI: 10.1200/jco.2015.33.3\_suppl.412]

20 **Cedrés S**, Torrejon D, Martínez A, Martinez P, Navarro A, Zamora E, Mulet-Margalef N, Felip E. Neutrophil to lymphocyte ratio (NLR) as an indicator of poor prognosis in stage IV non-small cell lung cancer. *Clin Transl Oncol* 2012; **14**: 864-869 [PMID: 22855161 DOI: 10.1007/s12094-012-0872-5]

21 **Fessas P**, Naeem M, Pinter M, Marron TU, Szafron D, Balcar L, Saeed A, Jun T, Dharmapuri S, Gampa A, Wang Y, Khan U, Muzaffar M, Navaid M, Lee PC, Bulumulle A, Yu B, Paul S, Nimkar N, Bettinger D, Hildebrand H, Abugabal YI, Pressiani T, Personeni N, Nishida N, Kudo M, Kaseb A, Huang YH, Ang C, Pillai A, Rimassa L, Naqash AR, Sharon E, Cortellini A, Pinato DJ. Early Antibiotic Exposure Is Not Detrimental to Therapeutic Effect from Immunotherapy in Hepatocellular Carcinoma. *Liver Cancer* 2021; **10**: 583-592 [PMID: 34950181 DOI: 10.1159/000519108]

22 **Pinato DJ**, Gramenitskaya D, Altmann DM, Boyton RJ, Mullish BH, Marchesi JR, Bower M. Antibiotic therapy and outcome from immune-checkpoint inhibitors. *J Immunother Cancer* 2019; **7**: 287 [PMID: 31694714 DOI: 10.1186/s40425-019-0775-x]

23 **R Development Core Team.** A language and environment for statistical computing.Vienna**,** Austria: R Foundation for Statistical Computing. 2017; [DOI: 10.1109/sai.2017.8252085]

24 **Dougan M**, Luoma AM, Dougan SK, Wucherpfennig KW. Understanding and treating the inflammatory adverse events of cancer immunotherapy. *Cell* 2021; **184**: 1575-1588 [PMID: 33675691 DOI: 10.1016/j.cell.2021.02.011]

25 **Kennedy LB**, Salama AKS. A review of cancer immunotherapy toxicity. *CA Cancer J Clin* 2020; **70**: 86-104 [PMID: 31944278 DOI: 10.3322/caac.21596]

26 **Sibaud V**. Dermatologic Reactions to Immune Checkpoint Inhibitors : Skin Toxicities and Immunotherapy. *Am J Clin Dermatol* 2018; **19**: 345-361 [PMID: 29256113 DOI: 10.1007/s40257-017-0336-3]

27 **Bureš J**, Kohoutová D, Zavoral M. Gastrointestinal toxicity of systemic oncology immunotherapy. *Klin Onkol* 2022; **35**: 346-357 [PMID: 36443091 DOI: 10.48095/ccko2022346]

28 **Król A**, Gawlik T, Jarząb B. Endocrine complications of cancer immunotherapy. *Endokrynol Pol* 2018; **69**: 722-733 [PMID: 30618030 DOI: 10.5603/EP.a2018.0073]

29 **Tison A**, Quéré G, Misery L, Funck-Brentano E, Danlos FX, Routier E, Robert C, Loriot Y, Lambotte O, Bonniaud B, Scalbert C, Maanaoui S, Lesimple T, Martinez S, Marcq M, Chouaid C, Dubos C, Brunet-Possenti F, Stavris C, Chiche L, Beneton N, Mansard S, Guisier F, Doubre H, Skowron F, Aubin F, Zehou O, Roge C, Lambert M, Pham-Ledard A, Beylot-Barry M, Veillon R, Kramkimel N, Giacchero D, De Quatrebarbes J, Michel C, Auliac JB, Gonzales G, Decroisette C, Le Garff G, Carpiuc I, Vallerand H, Nowak E, Cornec D, Kostine M; Groupe de Cancérologie Cutanée, Groupe Français de Pneumo-Cancérologie, and Club Rhumatismes et Inflammations. Safety and Efficacy of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Disease: A Nationwide, Multicenter Cohort Study. *Arthritis Rheumatol* 2019; **71**: 2100-2111 [PMID: 31379105 DOI: 10.1002/art.41068]

30 **Smithy JW**, Faleck DM, Postow MA. Facts and Hopes in Prediction, Diagnosis, and Treatment of Immune-Related Adverse Events. *Clin Cancer Res* 2022; **28**: 1250-1257 [PMID: 34921018 DOI: 10.1158/1078-0432.CCR-21-1240]

31 **Maher VE**, Fernandes LL, Weinstock C, Tang S, Agarwal S, Brave M, Ning YM, Singh H, Suzman D, Xu J, Goldberg KB, Sridhara R, Ibrahim A, Theoret M, Beaver JA, Pazdur R. Analysis of the Association Between Adverse Events and Outcome in Patients Receiving a Programmed Death Protein 1 or Programmed Death Ligand 1 Antibody. *J Clin Oncol* 2019; **37**: 2730-2737 [PMID: 31116675 DOI: 10.1200/JCO.19.00318]

32 **Ricciuti B**, Genova C, De Giglio A, Bassanelli M, Dal Bello MG, Metro G, Brambilla M, Baglivo S, Grossi F, Chiari R. Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis. *J Cancer Res Clin Oncol* 2019; **145**: 479-485 [PMID: 30506406 DOI: 10.1007/s00432-018-2805-3]

33 **Haratani K**, Hayashi H, Chiba Y, Kudo K, Yonesaka K, Kato R, Kaneda H, Hasegawa Y, Tanaka K, Takeda M, Nakagawa K. Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non-Small-Cell Lung Cancer. *JAMA Oncol* 2018; **4**: 374-378 [PMID: 28975219 DOI: 10.1001/jamaoncol.2017.2925]

34 **Sato K**, Akamatsu H, Murakami E, Sasaki S, Kanai K, Hayata A, Tokudome N, Akamatsu K, Koh Y, Ueda H, Nakanishi M, Yamamoto N. Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab. *Lung Cancer* 2018; **115**: 71-74 [PMID: 29290265 DOI: 10.1016/j.lungcan.2017.11.019]

35 **Lisberg A**, Tucker DA, Goldman JW, Wolf B, Carroll J, Hardy A, Morris K, Linares P, Adame C, Spiegel ML, Wells C, McKenzie J, Ledezma B, Mendenhall M, Abarca P, Bornazyan K, Hunt J, Moghadam N, Chong N, Nameth D, Marx C, Madrigal J, Vangala S, Shaverdian N, Elashoff D, Garon EB. Treatment-Related Adverse Events Predict Improved Clinical Outcome in NSCLC Patients on KEYNOTE-001 at a Single Center. *Cancer Immunol Res* 2018; **6**: 288-294 [PMID: 29382669 DOI: 10.1158/2326-6066.CIR-17-0063]

36 **Freeman-Keller M**, Kim Y, Cronin H, Richards A, Gibney G, Weber JS. Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes. *Clin Cancer Res* 2016; **22**: 886-894 [PMID: 26446948 DOI: 10.1158/1078-0432.CCR-15-1136]

37 **Teulings HE**, Limpens J, Jansen SN, Zwinderman AH, Reitsma JB, Spuls PI, Luiten RM. Vitiligo-like depigmentation in patients with stage III-IV melanoma receiving immunotherapy and its association with survival: a systematic review and meta-analysis. *J Clin Oncol* 2015; **33**: 773-781 [PMID: 25605840 DOI: 10.1200/JCO.2014.57.4756]

38 **Cortellini A**, Buti S, Agostinelli V, Bersanelli M. A systematic review on the emerging association between the occurrence of immune-related adverse events and clinical outcomes with checkpoint inhibitors in advanced cancer patients. *Semin Oncol* 2019; **46**: 362-371 [PMID: 31727344 DOI: 10.1053/j.seminoncol.2019.10.003]

39 **Pinato DJ**, Marron TU, Mishra-Kalyani PS, Gong Y, Wei G, Szafron D, Sharon E, Saeed A, Jun T, Dharmapuri S, Naqash AR, Peeraphatdit T, Gampa A, Wang Y, Khan U, Muzaffar M, Navaid M, Lee CJ, Lee PC, Bulumulle A, Yu B, Paul S, Nimkar N, Bettinger D, Hildebrand H, Abugabal YI, Pressiani T, Personeni N, D'Alessio A, Kaseb AO, Huang YH, Ang C, Schneider J, Pillai A, Rimassa L, Goldberg KB, Pazdur R, Theoret M, Lemery S, Fashoyin-Aje ', Cortellini A, Pelosof L. Treatment-related toxicity and improved outcome from immunotherapy in hepatocellular cancer: Evidence from an FDA pooled analysis of landmark clinical trials with validation from routine practice. *Eur J Cancer* 2021; **157**: 140-152 [PMID: 34508996 DOI: 10.1016/j.ejca.2021.08.020]

40 **Dharmapuri S**, Özbek U, Lin JY, Sung M, Schwartz M, Branch AD, Ang C. Predictive value of neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in advanced hepatocellular carcinoma patients treated with anti-PD-1 therapy. *Cancer Med* 2020; **9**: 4962-4970 [PMID: 32419290 DOI: 10.1002/cam4.3135]

41 **Muhammed A**, D'Alessio A, Enica A, Talbot T, Fulgenzi CAM, Nteliopoulos G, Goldin RD, Cortellini A, Pinato DJ. Predictive biomarkers of response to immune checkpoint inhibitors in hepatocellular carcinoma. *Expert Rev Mol Diagn* 2022; **22**: 253-264 [PMID: 35236211 DOI: 10.1080/14737159.2022.2049244]

42 **Pavan A**, Calvetti L, Dal Maso A, Attili I, Del Bianco P, Pasello G, Guarneri V, Aprile G, Conte P, Bonanno L. Peripheral Blood Markers Identify Risk of Immune-Related Toxicity in Advanced Non-Small Cell Lung Cancer Treated with Immune-Checkpoint Inhibitors. *Oncologist* 2019; **24**: 1128-1136 [PMID: 31015312 DOI: 10.1634/theoncologist.2018-0563]

43 **Lee PY**, Oen KQX, Lim GRS, Hartono JL, Muthiah M, Huang DQ, Teo FSW, Li AY, Mak A, Chandran NS, Tan CL, Yang P, Tai ES, Ng KWP, Vijayan J, Chan YC, Tan LL, Lee MB, Chua HR, Hong WZ, Yap ES, Lim DK, Yuen YS, Chan YH, Aminkeng F, Wong ASC, Huang Y, Tay SH. Neutrophil-to-Lymphocyte Ratio Predicts Development of Immune-Related Adverse Events and Outcomes from Immune Checkpoint Blockade: A Case-Control Study. *Cancers (Basel)* 2021; **13** [PMID: 33804050 DOI: 10.3390/cancers13061308]

44 **Fujimoto A**, Toyokawa G, Koutake Y, Kimura S, Kawamata Y, Fukuishi K, Yamazaki K, Takeo S. Association between pretreatment neutrophil-to-lymphocyte ratio and immune-related adverse events due to immune checkpoint inhibitors in patients with non-small cell lung cancer. *Thorac Cancer* 2021; **12**: 2198-2204 [PMID: 34173724 DOI: 10.1111/1759-7714.14063]

45 **Basu A,** Kollengode KA, Rafatnia A, Manoli H, Danenberg G, Chakravartty E, Epstein AL, Pinski JK. Relationship between neutrophil lymphocyte ratio (NLR) and MDSC concentration in localized and metastatic castration resistant prostate cancer (mCRPC) patients. *Journal of Clinical Oncology* 2018; **36** Suppl 6: 338-338 [DOI: 10.1200/jco.2018.36.6\_suppl.338]

46 **Veglia F**, Perego M, Gabrilovich D. Myeloid-derived suppressor cells coming of age. *Nat Immunol* 2018; **19**: 108-119 [PMID: 29348500 DOI: 10.1038/s41590-017-0022-x]

47 **Mao Y**, Qu Q, Chen X, Huang O, Wu J, Shen K. The Prognostic Value of Tumor-Infiltrating Lymphocytes in Breast Cancer: A Systematic Review and Meta-Analysis. *PLoS One* 2016; **11**: e0152500 [PMID: 27073890 DOI: 10.1371/journal.pone.0152500]

48 **Väyrynen JP**, Väyrynen SA, Sirniö P, Minkkinen I, Klintrup K, Karhu T, Mäkelä J, Herzig KH, Karttunen TJ, Tuomisto A, Mäkinen MJ. Platelet count, aspirin use, and characteristics of host inflammatory responses in colorectal cancer. *J Transl Med* 2019; **17**: 199 [PMID: 31196200 DOI: 10.1186/s12967-019-1950-z]

49 **Szczepanek-Parulska E**, Adamska M, Korda O, Kosicka W, Skowrońska D, Świejkowska A, Tuzimek D, Dadej D, Krygier A, Ruchała M. Changes in complete blood count parameters influenced by endocrine disorders. *Endokrynol Pol* 2021; **72**: 261-270 [PMID: 34292577 DOI: 10.5603/EP.a2021.0059]

50 **Gasparyan AY**, Ayvazyan L, Mukanova U, Yessirkepov M, Kitas GD. The Platelet-to-Lymphocyte Ratio as an Inflammatory Marker in Rheumatic Diseases. *Ann Lab Med* 2019; **39**: 345-357 [PMID: 30809980 DOI: 10.3343/alm.2019.39.4.345]

51 **Mischler K**, Fischer JE, Zgraggen L, Kudielka BM, Preckel D, von Känel R. The effect of repeated acute mental stress on habituation and recovery responses in hemoconcentration and blood cells in healthy men. *Life Sci* 2005; **77**: 1166-1179 [PMID: 15978266 DOI: 10.1016/j.lfs.2005.03.006]

52 **Tazzyman S**, Lewis CE, Murdoch C. Neutrophils: key mediators of tumour angiogenesis. *Int J Exp Pathol* 2009; **90**: 222-231 [PMID: 19563607 DOI: 10.1111/j.1365-2613.2009.00641.x]

53 **van Kooten C**, Banchereau J. CD40-CD40 Ligand. *J Leukoc Biol* 2000; **67**: 2-17 [PMID: 10647992 DOI: 10.1002/jlb.67.1.2]

54 **Chapman LM**, Aggrey AA, Field DJ, Srivastava K, Ture S, Yui K, Topham DJ, Baldwin WM 3rd, Morrell CN. Platelets present antigen in the context of MHC class I. *J Immunol* 2012; **189**: 916-923 [PMID: 22706078 DOI: 10.4049/jimmunol.1200580]

55 **Ali RA**, Wuescher LM, Worth RG. Platelets: essential components of the immune system. *Curr Trends Immunol* 2015; **16**: 65-78 [PMID: 27818580]

56 **Zhu L**, Huang Z, Stålesen R, Hansson GK, Li N. Platelets provoke distinct dynamics of immune responses by differentially regulating CD4+ T-cell proliferation. *J Thromb Haemost* 2014; **12**: 1156-1165 [PMID: 24833264 DOI: 10.1111/jth.12612]

57 **Pauken KE**, Dougan M, Rose NR, Lichtman AH, Sharpe AH. Adverse Events Following Cancer Immunotherapy: Obstacles and Opportunities. *Trends Immunol* 2019; **40**: 511-523 [PMID: 31053497 DOI: 10.1016/j.it.2019.04.002]

58 **Abou-Alfa Ghassan K,** Lau G, Kudo M, Chan Stephen L, Kelley Robin K, Furuse J, Sukeepaisarnjaroen W, Kang YK, Dao TV, De Toni EN, Rimassa L, Breder V, Vasilyev A, Heurgué A, Tam VC, Mody K, Thungappa SCT, Ostapenko Y, Yau T, Azevedo S, Varela M, Cheng AL, Qin S, Galle PR, Ali S, Marcovitz M, Makowsky M, He P, Kurland JF, Negro A, Sangro B. Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma. *NEJM Evidence* 2022; 1: EVIDoa2100070 [DOI:10.1056/evidoa2100070]

59 **Pierrard J**, Seront E. Impact of the gut microbiome on immune checkpoint inhibitor efficacy-a systematic review. *Curr Oncol* 2019; **26**: 395-403 [PMID: 31896938 DOI: 10.3747/co.26.5177]

60 **Herbst DA**, Reddy KR. Risk factors for hepatocellular carcinoma. *Clin Liver Dis (Hoboken)* 2012; **1**: 180-182 [PMID: 31186882 DOI: 10.1002/cld.111]

**Footnotes**

**Institutional review board statement:** This study was reviewed and approved by the Ethics Committee of the Mount Sinai Health System and locally by the ethical committee of each participating site.

**Informed consent statement:** The retrospective nature of the study, along with the absence of patient identifiers and most patients being deceased, made it impracticable to obtain individual consent from the patients included in the analysis.

**Conflict-of-interest statement:** Rimassa L report consulting fees from AstraZeneca, Basilea, Bayer, BMS, Eisai, Elevar Therapeutics, Exelixis, Genenta, Hengrui, Incyte, Ipsen, IQVIA, Jazz Pharmaceuticals, MSD, Nerviano Medical Sciences, Roche, Servier, Taiho Oncology, Zymeworks; lecture fees from AstraZeneca, Bayer, BMS, Eisai, Incyte, Ipsen, Merck Serono, Roche, Servier; travel expenses from AstraZeneca; research grants (to institution) from Agios, AstraZeneca, BeiGene, Eisai, Exelixis, Fibrogen, Incyte, Ipsen, Lilly, MSD, Nerviano Medical Sciences, Roche, Zymeworks. Pressiani Treports consulting fees from Bayer, Ipsen, AstraZeneca; travel expenses from Roche; research grants (to institution) from Roche, Bayer, Astra Zeneca. Personeni N reports consulting fees from Amgen, Merck KGaA, Boehringer Ingelheim, IQVIA, Servier, Sanofi Aventis; lecture fees from Janssens, Astra Zeneca, Incyte; research grants (to institution) from Servier, Basilea; travel expenses from Amgen, Servier. Pinter M is an investigator for Bayer, BMS, Lilly, and Roche, he received speaker honoraria from Bayer, BMS, Eisai, and MSD, he is a consultant for Bayer, BMS, Ipsen, Eisai, Lilly, Roche, and MSD, and he received travel support from Bayer, BMS, and Roche. Scheiner B received travel support from AbbVie, Ipsen and Gilead. Bettinger D received consulting fees from Bayer Healthcare, Boston Scientific, and Shionogi. Lectures: Falk Foundation. A.C. received consulting fees from MSD, BMS, AstraZeneca, and Roche; speakers’ fee from AstraZeneca, MSD, Novartis, and Astellas. Pinato DJ received lecture fees from ViiV Healthcare and Bayer Healthcare, and travel expenses from BMS and Bayer Healthcare; consulting fees for Mina Therapeutics, EISAI, Roche, and Astra Zeneca; and received research funding (to institution) from MSD and BMS. Saeed A receives consulting fee from AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo/Astra Zeneca; Exelixis; Five Prime Therapeutics; Pfize, speakers fee from Daiichi Sankyo/Astra Zeneca and research funding from Actuate Therapeutics (Inst); Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Daiichi Sankyo/UCB Japan (Inst); Exelixis (Inst); Five Prime Therapeutics (Inst); KAHR Medical (Inst); Merck Sharp and Dohme (Inst); Seattle Genetics (Inst). Khan U receives honoraria from Cardinal Health, consulting fee from Bard Peripheral Vascular and travel expenses paid for by Bard Peripheral Vascular; Cardinal Health. Huang YH is a consultant for Bayer; Bristol-Myers Squibb; Eisai; Gilead Sciences; Lilly; MSD; Roche and received speaker honoraria from Bayer; Bristol-Myers Squibb; Eisai; Gilead Sciences; Lilly; MSD; Roche. Kesab AO receives honoraria from AstraZeneca; Bayer Health; Bristol-Myers Squibb; Eisai; Exelixis; Genentech/Roche; Merck and research funding from Adaptimmune (Inst); Bayer/Onyx (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); Hengrui Pharmaceutical (Inst); Merck (Inst). Pillai A received consulting fee from AstraZeneca; Eisai; Exelixis; Genentech; Replimune, research funding from Target Pharmasolutions and speaker honoraria from Simply Speaking PAH. All remaining authors have declared no conflicts of interest.

**Data sharing statement:** No additional data are available.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Unsolicited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** May 21, 2023

**First decision:** August 15, 2023

**Article in press:**

**Specialty type:** Oncology

**Country/Territory of origin:** United States

**Peer-review report’s scientific quality classification**

Grade A (Excellent): A

Grade B (Very good): B


Grade C (Good): C

Grade D (Fair): D

Grade E (Poor): 0

**P-Reviewer:** Dang SS, China; Liu K, China; Șurlin VM, Romania; Wu SZ, China **S-Editor:** Qu XL **L-Editor: P-Editor:** Qu XL

**Figure Legends**



**Figure 1 Study flow chart.** IrAEs: Immune-related adverse events; NLR: Neutrophil-lymphocyte ratio; PLR: Platelet-lymphocyte ratio.

**Table 1 Baseline patient characteristics, *n* (%)**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Variable** | **Category** | **No AEs or AEs grade < 2** | **AEs grade ≥ 2** | **OR** | **95%CI** | ***P* value** |
| *n* = 361 |  | 274 (76)1 | 87 (24) |  |  |  |
| Age (Median) |  | 65 | 64 | 0.99 | (0.97, 1.01) | 0.450 |
| Sex | Male | 222 (61) | 65 (18) | 1.00 |  |  |
|  | Female | 52 (14) | 22 (7) | 1.44 | (0.82, 2.56) | 0.206 |
| AFP (Median) |  | 115 | 29 | 1.00 | (1, 1) | 0.850 |
| Known cirrhosis | Yes | 201 (56) | 62 (17) | 0.90 | (0.53, 1.54) | 0.702 |
|  | No | 73 (20) | 25 (7) | 1.00 |  |  |
| Known PVT | Yes | 61 (17) | 18 (5) | 0.60 | (0.33, 1.1) | 0.100 |
|  | No | 124 (34) | 61 (17) | 1.00 |  |  |
| NLR | NLR ≤ 5 | 122 (34) | 62 (17) | 1.00 |  |  |
|  | NLR > 5 | 54 (15) | 16 (5) | 0.58 | (0.31, 1.1) | 0.096 |
|  | Unknown | 98 (27) | 9 (2) |  |  |  |
| PLR | PLR ≤ 300 | 145 (40) | 72 (20) | 1.00 |  |  |
|  | PLR > 300 | 31 (9) | 6 (2) | 0.39 | (0.16, 0.98) | 0.044 |
|  | Unknown | 98 (27) | 9 (2) |  |  |  |
| Child pugh class | A | 202 (56) | 74 (20) | 1.00 |  |  |
|  | B | 61 (17) | 13 (4) | 0.58 | (0.3, 1.12) | 0.105 |
|  | C | 7 (2) | 0 (0) | 0.00 | (0, Inf) | 0.986 |
|  | Unknown | 4 (1) | 0 (0) |  |  |  |
| HCV | Yes | 112 (31) | 41 (11) | 1.29 | (0.79, 2.09) | 0.305 |
|  | No | 162 (45) | 46 (13) | 1.00 |  |  |
| HBV | Yes | 59 (16) | 18 (5) | 0.95 | (0.53, 1.72) | 0.867 |
|  | No | 215 (60) | 69 (19) | 1.00 |  |  |
| EtOH | Yes | 48 (13) | 17 (5) | 1.14 | (0.62, 2.11) | 0.669 |
|  | No | 226 (63) | 70 (19) | 1.00 |  |  |
| NASH | Yes | 37 (10) | 8 (2) | 0.65 | (0.29, 1.45) | 0.292 |
|  | No | 237 (66) | 79 (22) | 1.00 |  |  |
| BCLCs | A | 9 (2) | 1 (1) | 1.00 |  |  |
|  | B | 66 (18) | 25 (7) | 3.41 | (0.41, 28.31) | 0.256 |
|  | C | 194 (53) | 61 (17) | 2.83 | (0.35, 22.79) | 0.328 |
|  | D | 4 (1) | 0 (0) | 0.00 | (0, Inf) | 0.985 |
|  | Unknown | 1 (1) | 0 (0) |  |  |  |
| Extra Hepatic Disease | Yes | 100 (28) | 36 (10) | 0.73 | (0.43, 1.23) | 0.239 |
|  | No | 87 (24) | 43 (12) | 1.00 |  |  |
|  | Unknown | 87 (24) | 8 (2) |  |  |  |
| ECOG | 0 | 168 (47) | 77 (21) | 1.00 |  |  |
|  | 1 | 18 (5) | 2 (1) | 0.24 | (0.05, 1.07) | 0.062 |
|  | Unknown | 88 (24) | 8 (2) |  |  |  |
| Steroid use | Yes | 57 (16) | 37 (10) | 2.74 | (1.61, 4.64) | 0.0002 |
|  | No | 190 (53) | 45 (12) |  |  |  |
|  | Unknown | 27 (7) | 5 (2) |  |  |  |
| Antibiotic use | Yes | 42 (12) | 14 (4) | 1.01 | (0.52, 1.98) | 0.95 |
|  | No | 205 (56) | 67 (19) |  |  |  |
|  | Unknown | 27 (7) | 6 (2) |  |  |  |
| Treatment | PD-1 | 244 (68) | 61 (17) |  |  |  |
|  | PD-1/CLTA-4 | 16 (4) | 12 (3) | 3.00 | (1.35, 6.67) | 0.007 |
|  | PD-1/TKI | 12 (3) | 12 (3) | 4.00 | (1.71, 9.34) | 0.001 |
|  | PD-1/other | 1 (0) | 1 (0) | 4.00 | (0.25, 64.86) | 0.329 |
|  | CTLA-4 | 1 (0) | 1 (0) | 4.00 | (0.25, 64.86) | 0.32 |

1Of 274 (76%) with no adverse events (AEs) or AEs grade < 2, 80 (22%) had grade 1 AEs and 194 (54%) had no AEs. OR: Odds ratio; CI: Confidence interval; AEs: Adverse events; AFP: Alpha-fetoprotein; ECOG: Eastern cooperative oncology group; BCLCs: Barcelona clinic liver cancers; NASH: Nonalcoholic steatohepatitis; HBV: Hepatitis B virus; HCV: Hepatitis C virus infection; PLR: Platelet-lymphocyte ratio; NLR: Neutrophil-lymphocyte ratio; PVT: Portal vein thrombosis; PD-1: Programmed cell death ligand 1; CLTA-4: Cytotoxic T-lymphocyte antigen-4; TKI: Tyrosine kinase inhibitor.

**Table 2 Immune-related adverse events incidence by groups1, *n* (%)**

|  |  |  |
| --- | --- | --- |
| **IrAE by organ system *n* = 167** | **Grade < 2** | **Grade ≥ 2** |
| Dermatological | 43 (26) | 15 (9) |
| Colitis | 19 (11) | 10 (6) |
| Hepatitis | 40 (24) | 29 (17) |
| Endocrine | 18 (11) | 11 (7) |
| Polyarthritis | 3 (1) | 1 (0) |
| Pneumonitis | 10 (6) | 9 (5) |
| Constitutional | 52 (31) | 15 (9) |
| Other | 15 (9) | 22 (13) |

1The incidence of immune-related adverse events (IrAEs) has been presented by patient groups categorized as those with IrAEs of grade < 2 and those with IrAEs of grade ≥ 2, stratified by the affected organ systems. IrAE: Immune-related adverse events.

**Table 3 Univariable and multivariable models to predict grade 2 or higher adverse events**

|  |  |  |  |
| --- | --- | --- | --- |
|  | **Odds ratio** | **95%CI** | ***P* value** |
| Univariable model: | | | |
| PLR (> 300) | 0.40 | (0.16, 0.98) | 0.044 |
| NLR (> 5) | 0.58 | (0.31, 1.10) | 0.097 |
| Steroid use | 2.74 | (1.62, 4.64) | < 0.001 |
| Antibiotics use | 1.02 | (0.52, 1.98) | 0.954 |
| Treatment |  |  |  |
| PD-1 CLTA-4 | 3 | (1.35, 6.67) | 0.007 |
| PD-1 TKI | 4 | (1.71, 9.34) | 0.001 |
| Other1 | 4 | (0.55, 28.97) | 0.170 |
| Multivariable model: | | | |
| PLR (> 300) | 0.26 | (0.09, 0.74) | 0.011 |
| Steroid use | 4.43 | (2.21, 8.88) | < 0.001 |
| Treatment | | | |
| PD-1/CLTA-4 | 2.57 | (1.06, 6.24) | 0.037 |
| PD-1/TKI | 3.39 | (1.34, 8.56) | 0.01 |
| Other1 | 3.50 | (0.21, 57.86) | 0.381 |

1Other include single agent cytotoxic t-lymphocyte antigen-4 and other immune checkpoint inhibitors/tyrosine kinase inhibitor combinations. CI: Confidence interval; PLR: Platelet-lymphocyte ratio; NLR: Neutrophil-lymphocyte ratio; PD-1: Programmed cell death ligand 1; CLTA-4: Cytotoxic t-lymphocyte antigen-4; TKI: Tyrosine kinase inhibitor.